P

PROCEPT BioRobotics

Biotech & Life Sciences · Redwood City, United States · Founded 2009 · IPO 2021

PROCEPT BioRobotics is a pioneering medical technology company specializing in the development of advanced robotic solutions for the treatment of benign prostatic hyperplasia (BPH). BPH is a common condition in older men that causes enlargement of the prostate gland, leading to uncomfortable urinary symptoms. The company's flagship product, the AquaBeam Robotic System, performs Aquablation therapy, which is a minimally invasive surgical procedure that uses a combination of real-time imaging, robotics, and waterjet technology to remove prostate tissue with high precision. PROCEPT BioRobotics primarily serves urologists and healthcare institutions that treat patients suffering from BPH. The company operates in the medical device market, focusing on innovative surgical solutions that improve patient outcomes and streamline surgical procedures. The business model of PROCEPT BioRobotics revolves around the sale and distribution of the AquaBeam Robotic System and associated consumables. The company generates revenue through the initial sale of the robotic system to hospitals and clinics, as well as recurring revenue from the sale of disposable components required for each procedure. Additionally, PROCEPT offers training and support services to ensure that healthcare providers can effectively utilize their technology. PROCEPT BioRobotics has established itself as a leader in the field by providing a solution that offers predictable and reproducible outcomes, reducing the risk of complications and improving the quality of life for patients. The company's technology has been recognized and included in clinical practice guidelines, further solidifying its position in the market. Keywords: Aquablation, AquaBeam, BPH treatment, robotic surgery, medical technology, urology, prostate health, minimally invasive, healthcare innovation, surgical precision.